These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30303652)

  • 41. Combination therapies targeting multiple pathways in idiopathic pulmonary fibrosis (IPF).
    Taniguchi H; Kondoh Y
    Intern Med; 2013; 52(22):2481-2. PubMed ID: 24240784
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluating new treatment options.
    Nathan SD
    Am J Manag Care; 2017 Jul; 23(11 Suppl):S183-S190. PubMed ID: 28978213
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis.
    Bando M; Yamauchi H; Ogura T; Taniguchi H; Watanabe K; Azuma A; Homma S; Sugiyama Y;
    Intern Med; 2016; 55(5):443-8. PubMed ID: 26935361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Novel therapies for idiopathic pulmonary fibrosis].
    Wand O; Kremer MR
    Harefuah; 2015 Jul; 154(7):446-50, 469, 468. PubMed ID: 26380465
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?
    Papiris SA; Kagouridis K; Kolilekas L; Triantafillidou C; Tsangaris I; Manali ED
    Eur Respir J; 2012 Sep; 40(3):794-5. PubMed ID: 22941551
    [No Abstract]   [Full Text] [Related]  

  • 46. Eosinophilic pneumonia associated with pirfenidone therapy.
    Gomez DC; Mehrad B
    Eur Respir J; 2016 Oct; 48(4):1240-1242. PubMed ID: 27390279
    [No Abstract]   [Full Text] [Related]  

  • 47. Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?
    Inchingolo R; Condoluci C; Smargiassi A; Mastrobattista A; Boccabella C; Comes A; Golfi N; Richeldi L
    Expert Opin Pharmacother; 2017 Oct; 18(15):1583-1594. PubMed ID: 28933616
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of pirfenidone in patients with an acute exacerbation of interstitial pneumonia.
    Matsumura T; Tsushima K; Abe M; Suzuki K; Yamagishi K; Matsumura A; Ichimura Y; Ikari J; Terada J; Tatsumi K
    Clin Respir J; 2018 Apr; 12(4):1550-1558. PubMed ID: 28876508
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pirfenidone in idiopathic pulmonary fibrosis.
    Swigris J; Fairclough D
    Eur Respir J; 2010 Sep; 36(3):695-6; author reply 696-8. PubMed ID: 20930209
    [No Abstract]   [Full Text] [Related]  

  • 50. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis.
    Loeh B; Drakopanagiotakis F; Bandelli GP; von der Beck D; Tello S; Cordani E; Rizza E; Barrocu L; Markart P; Seeger W; Guenther A; Albera C
    Am J Respir Crit Care Med; 2015 Jan; 191(1):110-3. PubMed ID: 25551350
    [No Abstract]   [Full Text] [Related]  

  • 51. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
    Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ
    Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Idiopathic pulmonary fibrosis: pathogenesis and management.
    Sgalla G; Iovene B; Calvello M; Ori M; Varone F; Richeldi L
    Respir Res; 2018 Feb; 19(1):32. PubMed ID: 29471816
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
    Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
    Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
    Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Idiopathic Pulmonary Fibrosis.
    Lederer DJ; Martinez FJ
    N Engl J Med; 2018 May; 378(19):1811-1823. PubMed ID: 29742380
    [No Abstract]   [Full Text] [Related]  

  • 56. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.
    Arai T; Inoue Y; Sasaki Y; Tachibana K; Nakao K; Sugimoto C; Okuma T; Akira M; Kitaichi M; Hayashi S
    Respir Investig; 2014 Mar; 52(2):136-43. PubMed ID: 24636270
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Idiopathic pulmonary fibrosis: the turning point is now!
    Funke M; Geiser T
    Swiss Med Wkly; 2015; 145():w14139. PubMed ID: 26024356
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comment on: CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis.
    Rea G; Bocchino M
    Eur J Radiol; 2014 Oct; 83(10):1988-9. PubMed ID: 25084686
    [No Abstract]   [Full Text] [Related]  

  • 59. Developments in the management of idiopathic pulmonary fibrosis.
    Drug Ther Bull; 2015 Jul; 53(7):78-81. PubMed ID: 26159700
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events.
    Costabel U; Bendstrup E; Cottin V; Dewint P; Egan JJ; Ferguson J; Groves R; Hellström PM; Kreuter M; Maher TM; Molina-Molina M; Nordlind K; Sarafidis A; Vancheri C
    Adv Ther; 2014 Apr; 31(4):375-91. PubMed ID: 24639005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.